Cart
sales@molnova.com
Abciximab
CAS No. 143653-53-6
Abciximab( —— )
Catalog No. M36740 CAS No. 143653-53-6
Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 324 | Get Quote |
|
| 5MG | 535 | Get Quote |
|
| 10MG | 842 | Get Quote |
|
| 25MG | 1224 | Get Quote |
|
| 50MG | 1638 | Get Quote |
|
| 100MG | 2187 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAbciximab
-
NoteResearch use only, not for human use.
-
Brief DescriptionAbciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor.
-
DescriptionAbciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor. Abciximab inhibits platelet aggregation and leucocyte adhesion by binding to the glycoprotein IIb/IIIa, vitronectin and Mac-1 receptors.
-
In VitroAbciximab (C7E3) inhibits platelet aggregation induced by physiologic and pathologic agonists by binding to the platelet αIIbβ3 integrin.Abciximab appears to have similar affinity for the αIIbβ3 and αvβ3 integrins and redistributes between them.
-
In VivoAbciximab (C7E3) (0.25 mg/kg/day; i.v.; 28 days) effectively prevents neointimal hyperplasia.Animal Model:Male Wistar rats weighing 200-250 g, balloon angioplasty model Dosage:0.25 mg/kg/day Administration: Intravenous injection, 28 days Result:Time-dependently inhibited both neointimal hyperplasia and lumen occlusion after angioplasty in carotid arteries of rats. Significantly reduced PDGF-BB expression in vessel lumens and neointimal smooth muscle cells after angioplasty. Suppressed the elevation of plasma TxB2 concentration.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetIntegrin
-
RecptorIntegrin
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number143653-53-6
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ibbotson T, et al. Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs. 2003;63(11):1121-63.?
molnova catalog
related products
-
Tadocizumab
Tadocizumab (C4G1) is a humanized monoclonal antibody targeting integrin αIIbβ3 with antiplatelet and antithrombotic activity that blocks the platelet αIIbβ3 integrin interac- with brinogen and bronectin, and can be used in the study of cardiovascular disease.
-
Cyclo(RGDyK)
Cyclo(RGDyK) is a potent and selective αVβ3 integrin inhibitor with IC50 of 20 nM.
-
CWHM-12
A novel active RGD peptidomimetic inhibitor of αv integrin with IC50s of 1.8/0.8/61/1.5/0.2 nM for αvβ1/αvβ3/αvβ5/αvβ6/αvβ8; no inhibition on αIIbβ3, α2β1 and α10β1 (>50 uM).
